🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Manning & Napier Group’s BBIO Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+29 Shares
Current Position
29 Shares
$2,088 Value

Manning & Napier Group's BBIO Position Overview

Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 29 shares of BridgeBio Pharma, Inc. (BBIO) worth $2,088, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Manning & Napier Group has initiated a new position in BBIO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Manning & Napier Group's BridgeBio Pharma (BBIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly BridgeBio Pharma (BBIO) Trades by Manning & Napier Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +29 New Buy 29 $72.00

Manning & Napier Group's BridgeBio Pharma Investment FAQs

Manning & Napier Group first purchased BridgeBio Pharma, Inc. (BBIO) in Q2 2026, acquiring 29 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group has held BridgeBio Pharma, Inc. (BBIO) for 1 quarters since Q2 2026.

Manning & Napier Group's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q2 2026, adding 29 shares worth $2,088.

According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 29 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $2,088.

As of the Q2 2026 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.

Manning & Napier Group's peak holding in BridgeBio Pharma, Inc. (BBIO) was 29 shares, as reported at the end of Q2 2026.